Key Highlights

● DaVita closed at $178.97 on 9 October 2026.

● Market data consensus target is $233.43, implying about 30.4% upside.

● The second data set shows a mean of $219.86 and a median of $220.

● TD Cowen upgraded the shares on 7 August with a $220 target.

DaVita (NYSE:DVA), a kidney-care services provider and S&P 500 constituent, closed at $178.97 on Friday 9 October 2026. The shares trade below the analyst consensus target, with a wide range of views among brokers.

What Is the Latest Analyst Price Target?

Market data shows a consensus price target of $233.43 from seven analysts with ratings in the past 12 months, implying upside of about 30.4% from the $178.97 close. The range runs from $215 to $270.

The second data set, using third-party data, shows a lower mean of $219.86 and a median of $220 from eight analysts, with a range of $165 to $270.

The two data sets differ by roughly $14 on the mean, partly because the second data set includes a low target of $165 that market data does not show.

What Are Wall Street Analysts Saying?

Market data lists four Buy and three Hold ratings with no Sells, a Moderate Buy consensus. The second data set is more cautious, counting three Strong Buy, four Hold and one Sell.

Named broker actions show a split between optimists and cautious analysts. UBS raised its target from $235 to $270 with a Buy rating in July, and Deutsche Bank reiterated Buy with a $265 target in August. On 7 August, TD Cowen upgraded the shares from Hold to Buy and raised its target from $201 to $220. Oppenheimer and Raymond James set $220 targets on the same day, while Truist cut its target from $250 to $215 with a Hold rating. Barclays raised its target from $218 to $224 with an Equal Weight rating.

An independent ratings service upgraded the shares to Buy (B-) on 9 October, while a second ratings service downgraded them to Hold in July. Both are quantitative rating services rather than traditional broker research.

What Could Help the Stock Reach the Price Target?

The upside implied by the consensus suggests analysts see value if the company delivers on earnings expectations. The TD Cowen upgrade in August indicates that at least one broker became more positive on the outlook.

These remain general considerations.

What Could Prevent the Stock Reaching the Target?

Analyst views are widely dispersed, from a $165 low in the second data set data to a $270 high. Truist's target cut shows that not every broker has become more optimistic, and the large spread suggests substantial uncertainty.

Healthcare services companies can be affected by reimbursement policy, labour costs, patient volumes and regulatory changes. Any of these could pressure margins and lead analysts to reduce their targets.

What Should Investors Watch Next?

After the next report, it will be worth watching whether analysts revise their targets, whether the ratings split changes, and whether the gap between the two data sets' averages narrows.

DaVita's Spread of Targets From $165 to $270

DaVita closed at $178.97 on 9 October 2026, with the market data consensus of $233.43 implying about 30.4% upside and the second data set's $219.86 a smaller gap. Ratings run from Buy to Sell depending on the data set, and the highest target, $270, belongs to UBS.